Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-26-335003
Filing Date
2026-08-05
Accepted
2026-08-05 16:01:46
Documents
90
Period of Report
2026-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q srpt-20260630.htm   iXBRL 10-Q 4827863
2 EX-10.3 srpt-ex10_3.htm EX-10.3 138747
3 EX-10.4 srpt-ex10_4.htm EX-10.4 94219
4 EX-31.1 srpt-ex31_1.htm EX-31.1 13732
5 EX-31.2 srpt-ex31_2.htm EX-31.2 13776
6 EX-32.1 srpt-ex32_1.htm EX-32.1 9900
7 EX-32.2 srpt-ex32_2.htm EX-32.2 9804
  Complete submission text file 0001193125-26-335003.txt   16257357

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT srpt-20260630.xsd EX-101.SCH 1651319
94 EXTRACTED XBRL INSTANCE DOCUMENT srpt-20260630_htm.xml XML 3277317
Mailing Address 215 FIRST STREET SUITE 415 CAMBRIDGE MA 02142
Business Address 215 FIRST STREET SUITE 415 CAMBRIDGE MA 02142 617-274-4000
Sarepta Therapeutics, Inc. (Filer) CIK: 0000873303 (see all company filings)

EIN.: 930797222 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-14895 | Film No.: 261243224
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)